Mass Suspension of Medical Device Registrations, Guidance on Post-market Clinical Monitoring Report Issued Simultaneously! Russia’s Regulatory Closed-Loop Takes Effect
Views:79
Time:2026-11-17 13:54:54


Recently, Russia’s medical device regulator has rolled out a series of major regulatory updates. Roszdravnadzor, the Russian healthcare regulator, has suspended the registration validity of a large number of medical devices. Shortly after, VNIIIMT (All-Russian Research Institute for Medical Devices) officially released methodological guidance for compiling PKM reports. With enforcement actions paired with supporting guidance, Russia has formed a closed-loop regulatory framework for post-market clinical monitoring of high-risk medical devices. Manufacturers exporting medical devices to Russia must pay close attention.



原
文
链
接


https://pharmvestnik.ru/content/news/roszdravnadzor-massovo-priostanavlivaet-registraciu-medizdelii.html


https://vademec.ru/news/2026/10/30/vniiimt-podgotovil-metodicheskie-rekomendatsii-po-otchetam-o-klinicheskom-monitoringe-medizdeliy/

一、Regulatory Crackdown: Multiple Enterprises Have Registrations Suspended for Failure to Submit PKM Reports



Russia’s healthcare regulator recently took centralized enforcement action against medical device registrations. A total of 47 products had their registration validity suspended for failing to submit post-market clinical monitoring (PKM) reports before the deadline. The affected products are mainly Class 26 implantable devices and Class 3 high-risk medical devices, categories that are legally required to conduct mandatory PKM.

This enforcement is based on Russian Ministry of Health Order No.541h, which took effect on September 1, 2026, replacing the old Order No.1113h. The core change: all PKM reports must be submitted exclusively via Roszdravnadzor’s automated information system. Submissions by email, paper copies or other channels will no longer be accepted.

Many manufacturers mistakenly believe the electronic submission rule is merely a channel adjustment, overlooking the associated penalty provisions. If a report is overdue, registration validity will be suspended, triggering a 30-day remedial grace period. The registration may be reinstated once the supplementary documents are submitted within the grace period. Further sanctions will apply if the report is still not submitted after the grace period, and the product cannot be legally circulated in Russia.

Industry experts have identified key pain points for many enterprises. Many non-Russian manufacturers and their Russian authorized representatives know they need to submit reports, but lack clarity on reporting standards and how to obtain local Russian data.On one hand, Russian medical institutions are not obligated to proactively provide clinical follow-up data to enterprises. Companies need to negotiate cooperation with hospitals in advance and build follow-up systems; long-term follow-up for implantable products is especially challenging. On the other hand, non-Russian vendors face a long stakeholder chain involving original manufacturers, authorized representatives, distributors and medical institutions, making data collection complicated and difficult to implement. Most enterprises are not willfully violating rules; rather, they do not know what constitutes a qualified PKM report, and submissions are frequently rejected during review.

Given the widespread ambiguity over standards in the industry, VNIIIMT, the body responsible for technical assessment, has promptly released practical operational guidance.


二、Recap of Statutory Obligations



Order No.541h entered into force on September 1, establishing the single online submission channel. Under Order No.541h: The manufacturer or its Russian authorized representative shall submit electronic post-market clinical monitoring reports annually for 3 consecutive years starting from the year after registration approval.


The annual submission deadline is no later than February 1st. Submissions are only accepted through Roszdravnadzor’s automated information system.
New clinical trials are not required for post-market monitoring; data shall be derived from real clinical use of the device within Russia.
Reports undergo technical assessment by VNIIIMT, with a review cycle of 120 working days. The final decision is issued by Roszdravnadzor.
Consequences for overdue submission: The medical device registration will be suspended for 30 working days. Enterprises may supplement reports within this 30-day grace period. Failure to submit after the grace period carries risks of further adverse action against the registration certificate.

三、VNIIIMT Releases Methodology for PKM Report Compilation



This methodological guidance, jointly developed by VNIIIMT and the expert committee of Roszdravnadzor’s National Institute for Quality, is not a mandatory regulation. However, it directly represents the review criteria, aligns with Orders No.540h and No.541h, and serves as the most critical reference document for report drafting and reducing rejection rates.

The guidance clarifies that reports must not only list adverse event complaints. Both positive and negative clinical outcomes from product use must be analyzed. Hospital subjective feedback alone without supporting original clinical records cannot serve as proof of product safety and performance. Overseas clinical data can only be used as supplementary reference; core evidence must come from local clinical practice in Russia.

A complete report shall include:
  • Residual risk list of the product
  • Records of adverse events and corrective and preventive actions implemented by the enterprise
  • Monitoring objectives and a complete monitoring plan for this monitoring cycle
  • Local clinical data generated by Russian medical institutions, with information of collaborating medical institutions specified
  • Data evaluation and analysis, and comprehensive conclusions on product safety and performance
Reports fall into three categories:initial reports, annual follow-up reports and final summary reports. The final summary report submitted in the third year must aggregate all three years of data and complete a comprehensive analytical assessment.

Core review criteria (attached in the appendix of the guidance):
  • Whether local Russian post-market clinical data was obtained within the reporting period
  • Whether the target patient population, product batches and different model versions are clearly specified
  • Whether supporting evidentiary documents issued by medical institutions are available

The document also specifies scenarios where the monitoring period may be extended for an additional 3 years:
  • Insufficient clinical data obtained
  • Available data cannot adequately demonstrate product safety and performance
  • The enterprise fails to implement necessary corrective and preventive actions


四、Scenarios That May Trigger Monitoring Obligations



Registration variations may also trigger additional post-market monitoring obligations, a point easily overlooked by many export enterprises. After registration approval, certain registration dossier revisions may require additional post-market clinical monitoring, including but not limited to:
 
  • Expanding product model series
  • Expanding clinical scope of use or modifying indications
  • Changes to the target patient population
  • Adjustments to implantation methods
  • New functional modules added to AI medical device software

When carrying out registration variations, enterprises must assess in advance whether additional monitoring obligations are triggered, instead of focusing only on the variation approval itself.


五、Practical Recommendations for Chinese Medical Device Manufacturers Exporting to Russia



Distinguish mandatory regulatory requirements and guidance documents:Order No.541h is legally binding, while the VNIIIMT methodology guidance is for practical reference. Reports must be prepared against this guidance to reduce rejection risk.
Prioritize data sources:Local Russian data > overseas data. Do not use domestic or European/American clinical data as core evidence for Russian local monitoring.
Plan data sources early:Do not rush to collect hospital data at the end of January each year. When revising registration dossiers, assess whether new monitoring tasks are required.

Understand the 30-day grace period is not an extension allowance:The grace period is only a remedial window. Once registration suspension is triggered, product sales in Russia will be halted immediately, resulting in commercial losses.


六、Closing Remarks



The market access logic for high-risk medical devices in Russia has undergone fundamental changes. Registration approval is merely an entry ticket, while routine post-market clinical monitoring is a long-term requirement to retain market access. Amid intensified regulatory enforcement and clarified review criteria, enterprises must build a compliant closed-loop system in advance and steadily accumulate local Russian clinical data to avoid registration suspension risks and develop the Russian market sustainably.If you require further information, please contact Wiselink.


Contact Us
Fill Form
Whether you need more information or wish to cooperate with us, we will guide you through every step of the regulatory process. Subscribe to our newsletter for the latest global regulatory updates.